Germany approved a substantial increase in rebates on patented drugs, raising pressure on pricing models across the biopharma sector. The policy increases rebates from 7% to 15.5% for patented drugs and sets a 9% rebate for patented vaccines, alongside a price-freeze through 2030 and price-volume controls. The change matters for commercial forecasting because it adds direct margin compression and constrains spend growth through volume-linked mechanisms. For companies with portfolios exposed to German statutory rebate structures, the policy increases the importance of real-world performance and contracting strategy. The broader industry implication is that health-system cost containment remains active even as new modalities launch, forcing continued prioritization of lifecycle economics rather than only pipeline value.